The Global Sexually Transmitted Diseases (STD) Testing Market size is expected to reach $119.95 billion by 2027, rising at a market growth of 4.5% CAGR during the forecast period.
Infections transmitted from an infected person to an uninfected person through sexual intercourse are known as sexually transmitted diseases (STDs). Vaginal, oral, or anal sex are the most common forms of sexual contacts through which STDs get transmitted. Additionally, these diseases can spread through other forms of intimate physical contact also. This is due to the fact that some STDs, such as herpes and HPV, are spread through skin-to-skin contact since some of them are caused by Bacteria, viruses, or parasites. Gonorrhea, genital herpes, human papillomavirus infection, HIV/AIDS, chlamydia, and syphilis are only a few examples of STDs.
HIV/AIDS has consistently rated among the top ten leading causes of death for decades. In developed countries, testing and treatment have considerably reduced the disease's impact and prevalence. However, among younger groups, there has been a substantial increase in infection rates.
The COVID-19 pandemic is a public health disaster that has a negative impact on the STD testing market. Sexually transmitted infection cases were high prior to the pandemic, but following the pandemic, STD testing cases have reduced. Due to difficulties in health care and sexually transmitted infection testing services during the early months of the COVID-19 pandemic, testing reports of sexually transmitted infections were declined.
Due to a scarcity of intensive care resources, efforts were concentrated on ensuring the availability of critical care services. In addition, the imposition of restrictions like the ban on imports & exports and disruption in the supply chain have hampered the demand for STD testing kits and hence, hinder the growth of the STD testing market in the upcoming years.
There are many governments across developed and developing nations who are trying to aware people regarding the importance of early testing of STDs. For this, government and other healthcare authorities have strategized various campaigns for creating awareness among people regarding STDs. For example, CDC has initiated STD Awareness Week, which held in the second week of April. Also, many other renowned healthcare organizations are running campaigns for the same in their respective regions or even worldwide.
Several government authorities are increasing their investment in the development of fast and effective STD testing since it helps them to control the cases of STDs by providing correct medications at the correct time. The death rate of people having STDs is significantly high because patients do not get tested with correct measures at right time, which makes their condition more vulnerable and difficult to treat.
People seeking STI testing and treatment face numerous issues. Limited resources, poor service quality, and little or no sexual partner follow-up are among them. STI services are given independently in many countries and are not included in primary health care, family planning, or other regular health treatments. Because of a shortage of qualified employees, laboratory capacity, and adequate supply of relevant medicines, many services are unable to perform screening for asymptomatic infections.
Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Gonorrhea segment is estimated to garner a substantial share in the market during the forecast period. The bacteria Neisseria gonorrhoeae causes gonorrhoea, which is a sexually transmitted illness (STD).
Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Point of care testing refers to the medical diagnostic testing done in the nearby care center. People who have not undergone professional laboratory training can also undertake POC testing.
| Report Attribute | Details |
|---|---|
| Market size value in 2020 | USD 90.7 Billion |
| Market size forecast in 2027 | USD 120 Billion |
| Base Year | 2020 |
| Historical Period | 2017 to 2019 |
| Forecast Period | 2021 to 2027 |
| Revenue Growth Rate | CAGR of 4.5% from 2021 to 2027 |
| Number of Pages | 193 |
| Number of Tables | 284 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling |
| Segments covered | Disease Type, Location of Testing, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia-Pacific emerged as the leading region in the sexually transmitted diseases market with the largest revenue share and is projected to continue this trend during the forecast period. This is due to an increase in the number of cases of sexually transmitted illnesses in developing countries like China and Japan.
Free Valuable Insights: Global Sexually Transmitted Diseases (STD) Testing Market size to reach USD 120 Billion by 2027
The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. is the major forerunner in the Sexually Transmitted Diseases (STD) Testing Market. Companies such as Abbott Laboratories, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc. are some of the key innovators in the Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.
By Disease Type
By Location of Testing
By Geography
The global sexually transmitted diseases (STD) testing market size is expected to reach $119.95 billion by 2027.
Rising government investments or funds are driving the market in coming years, however, Weak health services for screening and curing STDs limited the growth of the market.
BioMerieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.
The Laboratory Testing market dominated the Global Sexually Transmitted Diseases (STD) Testing Market by Location of Testing 2020, growing at a CAGR of 3.8% during the forecast period.
The Asia Pacific market dominated the Global Sexually Transmitted Diseases (STD) Testing Market by Region 2020, and would continue to be a dominant market till 2027.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 